Grace Therapeutics D
D
GRCE
1.88000
USD
0.09
(5.03%)
Post Trading·1.88000USD0.00000(0.00%)
Last updated: · Delayed 15 min
Volume
825
EPS
-1
Div Yield
-
P/E
-2
Market Cap
39,547,548
Title: Grace Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipinefor the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.